. 2020 Apr 7;26(13):1501–1512. doi: 10.3748/wjg.v26.i13.1501

Table 3.

Univariate analysis in the validation cohort

Variables	Overall survival			Recurrence-free survival
Variables	HR	95%CI	P value	HR	95%CI	P value
Age	0.996	0.981-1.011	0.594	0.990	0.976-1.004	0.148
Gender, F/M	0.907	0.667-1.233	0.534	0.920	0.695-1.218	0.560
HBsAg	1.004	0.717-1.405	0.982	1.110	0.819-1.505	0.500
Hepatolithiasis	1.092	0.744-1.602	0.654	0.799	0.551-1.158	0.236
Child-Pugh grade, A /B	0.852	0.435-1.671	0.642	0.751	0.418-1.350	0.339
Ascites	1.440	0.871-2.382	0.155	1.580	1.004-2.487	0.048^a
CA-199, ≥ 22/< 22	1.744	1.390-2.188	< 0.001^a	1.402	1.140-1.722	0.001^a
Tumor size	1.054	0.997-1.115	0.064^a	1.084	1.030-1.141	0.002^a
Tumor number, Multiple/Single	1.845	1.344-2.531	< 0.001^a	1.874	1.397-2.513	< 0.001^a
Tumor differentiation, Moderate-Poor/Well	13.449	1.881-96.150	0.010	6.053	1.930-18.982	0.002^a
Macrovascular invasion	1.050	0.730-1.511	0.792	1.009	0.718-1.418	0.959
Microvascular invasion	1.995	1.228-3.242	0.005^a	2.023	1.290-3.172	0.002^a
Liver capsule invasion	1.553	1.118-2.159	0.009^a	1.280	0.955-1.716	0.099^a
Node-positive	2.009	1.438-2.808	< 0.001^a	1.525	1.115-2.085	0.008^a
Perineural invasion	1.366	0.906-2.059	0.136	1.262	0.867-1.838	0.225
Cirrhosis	0.984	0.686-1.412	0.932	1.054	0.762-1.459	0.749
TNM stage, III/I-II	1.774	1.242-2.533	0.002^a	1.413	1.035-1.929	0.029
BCLC, B-C/0-A	1.619	1.136-2.308	0.008^a	1.849	1.335-2.562	< 0.001^a
NLR, > 2.62/≤ 2.62	1.649	1.202-2.261	0.002^a	1.635	1.226-2.180	0.001^a
PLR, > 103/≤ 103	1.417	1.036-1.938	0.029^a	1.065	0.803-1.414	0.661
GLR, > 33.7/≤ 33.7	1.826	1.300-2.565	0.001^a	1.780	1.315-2.408	< 0.001^a

P < 0.10. M: Male; F: Female; HBV: Hepatitis B virus; CA-199: Carbohydrate antigen-199; TNM: Tumor-node-metastasis; BCLC: Barcelona Clinic Liver Cancer; NLR: Neutrophil to lymphocyte ratio; PLR: Platelet to lymphocyte ratio; GLR: Gamma-glutamyltransferase to lymphocyte ratio; HR: Hazard ratio; CI: Confidence interval.